Details for Patent: 12,268,662

« Back to Dashboard

Which drugs does patent 12,268,662 protect, and when does it expire?

Patent 12,268,662 protects YUVEZZI and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 12,268,662

Title:	Formulations comprising carbachol and brimonidine to enhance anti- presbyopia effects
Abstract:	The present disclosure is directed to ophthalmic formulations comprising carbachol, processes for preparing ophthalmic formulations comprising carbachol, and methods of treating presbyopia and other ophthalmic conditions by administering ophthalmic formulations comprising carbachol to a subject in need thereof.
Inventor(s):	Rhett Schiffman, Bruce FIRESTONE
Assignee:	Pharmassist Cmc Consulting LLC , Visus Therapeutics Inc
Application Number:	US18/531,082
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 12,268,662

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes			Y			TREATMENT OF PRESBYOPIA
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes			Y			USE OF YUVEZZI FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes			Y			TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF BRIMONIDINE AND CARBACHOL ONCE DAILY

International Family Members for US Patent 12,268,662

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	118541148
European Patent Office	4429652
Taiwan	202333662